EXACT Sciences (NASDAQ:EXAS) had its target price hoisted by stock analysts at BTIG Research from $60.00 to $70.00 in a research note issued on Wednesday. The brokerage currently has a “buy” rating on the medical research company’s stock. BTIG Research’s price objective would suggest a potential upside of 17.57% from the company’s current price.

Other analysts also recently issued research reports about the stock. BidaskClub raised shares of EXACT Sciences from a “hold” rating to a “buy” rating in a report on Thursday, March 8th. Leerink Swann set a $67.00 price objective on shares of EXACT Sciences and gave the company a “buy” rating in a research note on Friday, February 9th. Benchmark downgraded shares of EXACT Sciences from a “buy” rating to a “hold” rating in a research note on Friday, February 23rd. William Blair reissued a “buy” rating on shares of EXACT Sciences in a research note on Thursday, March 29th. Finally, ValuEngine raised shares of EXACT Sciences from a “hold” rating to a “buy” rating in a research note on Monday, April 2nd. One research analyst has rated the stock with a sell rating, five have issued a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $55.76.

Shares of EXACT Sciences opened at $59.54 on Wednesday, according to Marketbeat. EXACT Sciences has a 12-month low of $31.04 and a 12-month high of $63.60. The stock has a market capitalization of $6.43 billion, a price-to-earnings ratio of -60.14 and a beta of 0.86. The company has a current ratio of 15.30, a quick ratio of 14.86 and a debt-to-equity ratio of 0.71.

EXACT Sciences (NASDAQ:EXAS) last announced its quarterly earnings results on Thursday, April 26th. The medical research company reported ($0.33) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.38) by $0.05. EXACT Sciences had a negative net margin of 38.61% and a negative return on equity of 20.92%. The company had revenue of $90.30 million for the quarter, compared to the consensus estimate of $86.31 million. During the same quarter in the prior year, the firm earned ($0.32) earnings per share. The company’s revenue for the quarter was up 86.7% compared to the same quarter last year. equities analysts predict that EXACT Sciences will post -1.11 EPS for the current fiscal year.

In other EXACT Sciences news, Director Michael S. Wyzga sold 7,402 shares of the stock in a transaction that occurred on Thursday, May 10th. The shares were sold at an average price of $51.53, for a total transaction of $381,425.06. Following the transaction, the director now owns 10,974 shares of the company’s stock, valued at $565,490.22. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, SVP D Scott Coward sold 2,708 shares of the stock in a transaction that occurred on Monday, March 12th. The stock was sold at an average price of $52.19, for a total transaction of $141,330.52. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 50,791 shares of company stock worth $2,455,368. 4.00% of the stock is currently owned by insiders.

Large investors have recently bought and sold shares of the business. C M Bidwell & Associates Ltd. purchased a new position in EXACT Sciences during the fourth quarter worth approximately $117,000. Advisory Services Network LLC raised its stake in EXACT Sciences by 6,600.0% during the fourth quarter. Advisory Services Network LLC now owns 3,350 shares of the medical research company’s stock worth $176,000 after purchasing an additional 3,300 shares during the period. Quantbot Technologies LP purchased a new position in EXACT Sciences during the first quarter worth approximately $135,000. Bronfman E.L. Rothschild L.P. raised its stake in EXACT Sciences by 160.8% during the first quarter. Bronfman E.L. Rothschild L.P. now owns 3,464 shares of the medical research company’s stock worth $140,000 after purchasing an additional 2,136 shares during the period. Finally, Alps Advisors Inc. purchased a new position in EXACT Sciences during the fourth quarter worth approximately $210,000. 88.72% of the stock is currently owned by institutional investors.

About EXACT Sciences

Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer.

Analyst Recommendations for EXACT Sciences (NASDAQ:EXAS)

Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.